1α,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro

Journal of Endocrinology Volume 206 Issue 3 Page 279-286 published_at 2010-09
アクセス数 : 443
ダウンロード数 : 53

今月のアクセス数 : 5
今月のダウンロード数 : 4
File
JEndocrinol_206_279.pdf 229 KB 種類 : fulltext
Title ( eng )
1α,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro
Creator
Yamamoto Ryoko
Tanne Kazuo
Aubin Jane E
Maeda Norihiko
Source Title
Journal of Endocrinology
Volume 206
Issue 3
Start Page 279
End Page 286
Abstract
Osteoblasts/osteocytes are the principle sources of fibroblast growth factor 23 (FGF23), a phosphaturic hormone, but the regulation of FGF23 expression during osteoblast development remains uncertain. Because 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) and inorganic phosphate (Pi) may act as potent activators of FGF23 expression, we estimated how these molecules regulate FGF23 expression during rat osteoblast development in vitro. 1,25(OH)2D3-dependent FGF23 production was restricted largely to mature cells in correlation with increased vitamin D receptor (VDR) mRNA levels, in particular, when Pi was present. Pi alone and more so in combination with 1,25(OH)2D3 increased FGF23 production and VDR mRNA expression. Parathyroid hormone, stanniocalcin 1, prostaglandin E2, FGF2, and foscarnet did not increase FGF23 mRNA expression. Thus, these results suggest that 1,25(OH)2D3 may exert its largest effect on FGF23 expression/production when exposed to high levels of extracellular Pi in osteoblasts/osteocytes.
Descriptions
This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture of Japan (18592001 to YY) and the Canadian Institutes of Health Research (FRN 83704 to JEA).
Language
eng
Resource Type journal article
Publisher
Society for Endocrinology
Date of Issued 2010-09
Rights
© 2010 Society for Endocrinology. This is an Open Access article distributed under the terms of the Society for Endocrinology’s Re-use Licence which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Publish Type Version of Record
Access Rights open access
Source Identifier
[ISSN] 0022-0795
[ISSN] 1479-6805
[DOI] 10.1677/JOE-10-0058
[PMID] 20530653
[DOI] https://doi.org/10.1677/JOE-10-0058